RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2 Not yet recruiting 20 enrolled The First Affiliated Hospital of Zhengzhou University

NaSingle-groupOpen-labelTreatment

Summary

A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma

Timeline

Start: 2024-07-06
Primary completion: 2026-07-06
Completion: 2027-07-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadonilimab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Disitamab Vedotin	Monoclonal antibody	2.5 mg/kg	Intravenous

Indications

No indication recorded.